Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?
The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the terms of the deal, Novavax will receive an upfront payment of $30 million and ...
Jan 20 (Reuters) - Novavax said on Tuesday it has entered into a licensing agreement with Pfizer to develop vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results